Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exelixis to start cabozantinib Phase 2 IST study
The multi-center, open label, single arm trial will enroll 50 women with hormone receptor-positive breast cancer that has metastasized to the bone and whose disease has progressed after
The multi-center, open label, single arm trial will enroll 50 women with hormone receptor-positive breast cancer that has metastasized to the bone and whose disease has progressed after
Pfizer had entered into a 10-year lease agreement with MIT for over 180,000ft2 in September 2011. Pfizer has planned to switch its research and development, to lay more
The transaction, when completed, is expected to be dilutive to Gilead’s earnings through 2014 and accretive in 2015 and beyond. At present, Pharmasset’s three clinical-stage product candidates to
According to the company, the BioPharm Systems’ new service expands its clinical trial management practice offerings. The solution will help clinical research organizations to reduce cost, boost productivity,
The randomised, placebo controlled Phase I study is intended to assess the pharmacokinetics, safety and tolerability of orally administered multiple dose regimens of CNV2197944. Recently, ascending dose Phase
The ascending dose, double-blind, placebo-controlled study in healthy, non-smoking and smoking volunteers is designed to demonstrate the safety, tolerability and pharmacodynamic profile of the drug candidate. The study
The new approach combines synthetic chemistry with advanced screening technologies which would expand the number of provocative synthetic compounds available to explore as potential drug candidates. In addition,
Dexpramipexole, initially developed by Knopp Biosciences, is a novel drug which prevents dysfunction of mitochondria, the subcellular structures that provide most of a cell’s energy. The researchers devised
T89, also known as Dantonic pill, is a botanical product used to treat chronic stable angina pectoris due to coronary heart disease and aims to become the first
Erwinaze is an asparaginase enzyme which depletes asparagine level in the bloodstream. Asparagine helps in cell growth, and its removal from the blood inhibits the growth of cells